A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE ADVANCED OR RECURRENT (STAGE IIIB NOT AMENABLE FOR MULTIMODALITY TREATMENT) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER WHO ARE DEEMED UNSUITABLE FOR PLATINUM-CONTAINING THERAPY

Intervention/treatment:
TECENTRIQ / GEMCITABINE / VINORELBINE
Medical condition:
NON-SMALL CELL LUNG CANCER
Protocol code:
MO29872
Control number:
205342
Status:
Closed
Approved:
June 02, 2017
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03191786
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Medical Communications
Organization
Hoffmann-La Roche
Phone:
800-821-8590
Sponsor
HOFFMANN-LA ROCHE LIMITED

Locations

British Columbia

BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6

New Brunswick

Regional health authority A vitalite health network
Moncton, New Brunswick, E1C 8X3

Ontario

Ottawa Hospital Research Institute
Ottawa, Ontario, K1Y 4E9
Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5

Quebec

Jewish General Hospital
Montreal, Quebec, H3T 1E2

Results

See the results from the trial NCT03191786. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?